BioCentury | Feb 20, 2019
Distillery Therapeutics

Cancer

...estrogen receptor-positive breast cancer lines of analogs of the generic selective estrogen receptor modulator (SERM) raloxifene...
...of 0.77 nM. In one of the cell lines, the compound decreased growth compared with raloxifene...
...Next steps could include testing the compound in animal models of estrogen receptor-positive breast cancer. Raloxifene...
BioCentury | Mar 19, 2015
Targets & Mechanisms

Refertilizing endometriosis

...National Institute of Child Health and Human Development (NICHD) terminated a Phase II trial of raloxifene...
...enrollment for undisclosed reasons. Eli Lilly and Co. and Takeda Pharmaceutical Co. Ltd. market Evista raloxifene...
BioCentury | Oct 27, 2014
Finance

Waiting for better times

...in December, were off 73% to $368M, while sales of osteoporosis and cancer drug Evista raloxifene...
BioCentury | Jul 28, 2014
Finance

Staying the course with half a billion

...in December, were off 73% to $401M, while sales of osteoporosis and cancer drug Evista raloxifene...
BioCentury | Apr 28, 2014
Strategy

Shepherding growth

...exclusivity in December, fell 64% to $478.2 million. Sales of osteoporosis and cancer drug Evista raloxifene...
BioCentury | Apr 28, 2014
Finance

Venture hots up

...in December, were off 64% to $478.2M, while sales of osteoporosis and cancer drug Evista raloxifene...
BioCentury | Mar 10, 2014
Clinical News

Evista raloxifene regulatory update

...Industries Ltd. (NYSE:TEVA, Petah Tikva, Israel) for its generic version of Eli Lilly's Evista raloxifene. Evista...
...launch in the next 30 days. Lilly reported $772 million in 2013 U.S. sales of Evista...
...a selective estrogen receptor modulator (SERM). Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Evista raloxifene...
BioCentury | Feb 13, 2014
Distillery Therapeutics

Indication: Cancer

...block the IL-6-CD130 interaction and help treat cancer. Fragment-based drug design and virtual screening identified raloxifene...
...against the IL-6-CD130 interaction. Eli Lilly and Co. and Takeda Pharmaceutical Co. Ltd. market Evista raloxifene...
BioCentury | Sep 30, 2013
Clinical News

Evista raloxifene regulatory update

...use. Tamoxifen, an estrogen receptor antagonist, is available as a generic. Eli Lilly markets Evista raloxifene...
...raloxifene, a selective estrogen receptor modulator (SERM). Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Evista...
...a selective estrogen receptor modulator (SERM). Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Evista raloxifene...
BioCentury | Jul 22, 2013
Company News

Eli Lilly neurology, musculoskeletal, cancer news

...expiration of U.S. patents for neurology drug Cymbalta duloxetine and osteoporosis and cancer drug Evista raloxifene...
...protection for Cymbalta, a selective serotonin and norepinephrine reuptake inhibitor (SSNRI), in December and for Evista...
...Sales of Cymbalta in 2012 were up 20% to $5 billion, while 2012 sales of Evista...
Items per page:
1 - 10 of 117